Skip to content

glutamate

Articles tagged with “glutamate

12 articles
FDA Clears MIND1 Trial: NRX-101 Plus Robotic TMS for Suicidality — nrx 101 ketamine tms clinical trial fda 2026

FDA Clears MIND1 Trial: NRX-101 Plus Robotic TMS for Suicidality

The FDA has cleared the MIND1 trial testing NRX-101 plus robotic TMS for suicidality in treatment-resistant depression. What it means for ketamine patients.

Read
news

How Clinicians Choose TRD Treatments in 2026

New clinical guidance on treatment-resistant depression highlights how patient preference, speed of response, and functional outcomes shape ketamine treatment decisions.

news

Esketamine's Role in Treatment-Resistant Depression

A new clinical overview examines esketamine's place in TRD care, including patient selection, access barriers, and rapid-acting benefits for suicidal ideation.

news

Glutamate Pathway Treatments Reshape TRD Care in 2026

A 2026 review in Psychiatric Times highlights how esketamine and glutamate-targeting drugs are changing treatment-resistant depression care.

safety

Ketamine and Benzodiazepines: Clinical Interaction Guide

An evidence-based analysis of the interaction between ketamine and benzodiazepines, examining efficacy attenuation, timing considerations, clinical evidence, and management strategies for prescribers.

guides

The Complete Guide to Low-Dose Ketamine Therapy

A comprehensive, evidence-based guide covering what low-dose ketamine is, how it works, all routes of administration, what patients can expect during treatment, efficacy data across conditions, safety considerations, and how to find qualified providers.

research

Glutamate System Modulation by Low-Dose Ketamine

A comprehensive analysis of how low-dose ketamine modulates the glutamate system, including NMDA receptor antagonism, AMPA receptor potentiation, and the glutamate surge hypothesis. Reviews the excitatory-inhibitory balance framework and its therapeutic implications.

conditions

Low-Dose Ketamine for Social Anxiety Disorder: Preliminary Evidence

Examining preliminary evidence for low-dose ketamine in social anxiety disorder, including glutamatergic mechanisms, neuroimaging findings, and early-phase clinical data.

conditions

Ketamine for OCD: Glutamatergic Modulation of Obsessive-Compulsive Circuits

Review of ketamine in OCD treatment, examining glutamatergic modulation of cortico-striato-thalamo-cortical circuits, clinical trial evidence, and rapid anti-obsessional effects.

conditions

Low-Dose Ketamine for Anxiety Disorders

A clinical overview of subanesthetic ketamine's therapeutic potential in generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder, including mechanistic pathways, current evidence, and considerations for clinical practice.

research

Rapid-Onset Antidepressant Mechanisms of Low-Dose Ketamine

An in-depth examination of why and how low-dose ketamine produces antidepressant effects within hours rather than weeks. This article reviews the glutamatergic hypothesis, the role of spontaneous NMDA receptor activity, and emerging theories that distinguish ketamine from conventional antidepressants.

conditions

Low-Dose Ketamine for Treatment-Resistant Depression

An evidence-based overview of low-dose ketamine as a rapidly acting antidepressant for patients with treatment-resistant depression, including mechanisms of action, clinical protocols, and outcome data.

Contact Low Dose Ketamine

Send corrections, provider questions, or advertising inquiries.